» Articles » PMID: 28201779

Comprehensive Molecular Characterization of Multifocal Glioblastoma Proves Its Monoclonal Origin and Reveals Novel Insights into Clonal Evolution and Heterogeneity of Glioblastomas

Abstract

Background: The evolution of primary glioblastoma (GBM) is poorly understood. Multifocal GBM (ie, multiple synchronous lesions in one patient) could elucidate GBM development.

Methods: We present the first comprehensive study of 12 GBM foci from 6 patients using array-CGH, spectral karyotyping, gene expression arrays, and next-generation sequencing.

Results: Multifocal GBMs genetically resemble primary GBMs. Comparing foci from the same patient proved their monoclonal origin. All tumors harbored alterations in the 3 GBM core pathways: RTK/PI3K, p53, and RB regulatory pathways with aberrations of EGFR and CDKN2A/B in all (100%) patients. This unexpected high frequency reflects a distinct genetic signature of multifocal GBMs and might account for their highly malignant and invasive phenotype. Surprisingly, the types of mutations in these genes/pathways were different in tumor foci from the same patients. For example, we found distinct mutations/aberrations in PTEN, TP53, EGFR, and CDKN2A/B, which therefore must have occurred independently and late during tumor development. We also identified chromothripsis as a late event and in tumors with wild-type TP53. Only 2 events were found to be early in all patients: single copy loss of PTEN and TERT promoter point mutations.

Conclusions: Multifocal GBMs develop through parallel genetic evolution. The high frequency of alterations in 3 main pathways suggests that these are essential steps in GBM evolution; however, their late occurrence indicates that they are not founder events but rather subclonal drivers. This might account for the marked genetic heterogeneity seen in primary GBM and therefore has important implications for GBM therapy.

Citing Articles

Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated.

McDonald M, Gopakumar S, Juratli T, Eyupoglu I, Rao G, Mandel J Acta Neuropathol Commun. 2025; 13(1):9.

PMID: 39815367 PMC: 11737192. DOI: 10.1186/s40478-024-01900-1.


Multimodal treatment of glioblastoma with multiple lesions - a multi-center retrospective analysis.

Krenzlin H, Jankovic D, Dauth A, Lange F, Wetzel M, Schmidt L J Neurooncol. 2024; 170(3):555-566.

PMID: 39560695 PMC: 11614972. DOI: 10.1007/s11060-024-04810-3.


Chromatin Licensing and DNA Replication Factor 1 (CDT1) Is a Potential Prognostic Biomarker Involved in the Malignant Biological Behavior of Glioma.

Chen T, Meng J, Yu K, Huang T, Zhao J ACS Pharmacol Transl Sci. 2024; 7(10):3131-3143.

PMID: 39416957 PMC: 11475523. DOI: 10.1021/acsptsci.4c00312.


Multiple Glioblastomas Ablation by Laser Interstitial Thermal Therapy (LITT): A Rare Case.

Bakrbaldawi A, Al-Sheikh U, Jiang H, Zhu J Cureus. 2024; 16(8):e66726.

PMID: 39268310 PMC: 11392511. DOI: 10.7759/cureus.66726.


Patterns of care and survival in patients with multifocal glioblastoma: A Danish cohort study.

Trip A, Dahlrot R, Aaquist Haslund C, Muhic A, Korshoj A, Laursen R Neurooncol Pract. 2024; 11(4):421-431.

PMID: 39006522 PMC: 11241377. DOI: 10.1093/nop/npae020.


References
1.
Klink B, Schlingelhof B, Klink M, Stout-Weider K, Patt S, Schrock E . Glioblastomas with oligodendroglial component - common origin of the different histological parts and genetic subclassification. Anal Cell Pathol (Amst). 2010; 33(1):37-54. PMC: 4605661. DOI: 10.3233/ACP-CLO-2010-0530. View

2.
Gerstung M, Eriksson N, Lin J, Vogelstein B, Beerenwinkel N . The temporal order of genetic and pathway alterations in tumorigenesis. PLoS One. 2011; 6(11):e27136. PMC: 3206070. DOI: 10.1371/journal.pone.0027136. View

3.
Talasila K, Soentgerath A, Euskirchen P, Rosland G, Wang J, Huszthy P . EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 2013; 125(5):683-98. PMC: 3631314. DOI: 10.1007/s00401-013-1101-1. View

4.
Duesberg P . Does aneuploidy or mutation start cancer?. Science. 2005; 307(5706):41. DOI: 10.1126/science.307.5706.41d. View

5.
Sturm D, Witt H, Hovestadt V, Khuong-Quang D, Jones D, Konermann C . Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012; 22(4):425-37. DOI: 10.1016/j.ccr.2012.08.024. View